conjugated estrogens (Premarin)
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
1942 |
| gptkbp:ATCCode |
G03CA57
|
| gptkbp:brand |
gptkb:Premarin
|
| gptkbp:chemicalClass |
steroidal estrogen
|
| gptkbp:contains |
conjugated estrogens
|
| gptkbp:contraindication |
gptkb:cancer
liver dysfunction active thromboembolic disorder undiagnosed vaginal bleeding |
| gptkbp:derivedFrom |
pregnant mares' urine
|
| gptkbp:drugClass |
estrogen
|
| gptkbp:eliminationHalfLife |
7-9 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:butter
gptkb:tablet injectable |
| https://www.w3.org/2000/01/rdf-schema#label |
conjugated estrogens (Premarin)
|
| gptkbp:indication |
hormone replacement therapy
castration primary ovarian insufficiency ovarian failure vulvar and vaginal atrophy |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:monitors |
blood pressure
liver function thyroid function mammogram |
| gptkbp:pregnancyCategory |
X
|
| gptkbp:riskFactor |
gptkb:cardiovascular_disease
venous thromboembolism dementia (in women over 65) |
| gptkbp:routeOfAdministration |
oral
vaginal intravenous |
| gptkbp:sideEffect |
nausea
stroke headache breast tenderness increased risk of endometrial cancer thromboembolism |
| gptkbp:usedFor |
gptkb:cancer
prostate cancer hypoestrogenism menopausal symptoms osteoporosis prevention |
| gptkbp:bfsParent |
gptkb:17α-dihydroequilenin_sulfate
|
| gptkbp:bfsLayer |
7
|